Vascular Response to Overlapping Everolimus-Eluting Stents – Comparison With Paclitaxel-Eluting Stents –

Hiromasa Otake; Yasuhiro Honda; Masao Yamasaki; Ichizo Tsujino; Takao Shimohama; Ryota Sakurai; Takao Hasegawa; Katsuhisa Waseda; Junya Ako; Peter J. Fitzgerald

doi:10.1253/circj.CJ-10-0052

Rapid Communication

Vascular Response to Overlapping Everolimus-Eluting Stents

– Comparison With Paclitaxel-Eluting Stents –

Hiromasa Otake, Yasuhiro Honda, Masao Yamasaki, Ichizo Tsujino, Takao Shimohama, Ryota Sakurai, Takao Hasegawa, Katsuhisa Waseda, Junya Ako, Peter J. Fitzgerald

Author information

Hiromasa Otake
Center for Research in Cardiovascular Interventions, Stanford University
Yasuhiro Honda
Center for Research in Cardiovascular Interventions, Stanford University
Masao Yamasaki
Center for Research in Cardiovascular Interventions, Stanford University
Ichizo Tsujino
Center for Research in Cardiovascular Interventions, Stanford University
Takao Shimohama
Center for Research in Cardiovascular Interventions, Stanford University
Ryota Sakurai
Center for Research in Cardiovascular Interventions, Stanford University
Takao Hasegawa
Center for Research in Cardiovascular Interventions, Stanford University
Katsuhisa Waseda
Center for Research in Cardiovascular Interventions, Stanford University
Junya Ako
Center for Research in Cardiovascular Interventions, Stanford University
Peter J. Fitzgerald
Center for Research in Cardiovascular Interventions, Stanford University

Keywords: Everolimus-eluting stents, Intravascular ultrasound, Overlapping stenting

JOURNAL FREE ACCESS

2010 Volume 74 Issue 5 Pages 1023-1025

DOI https://doi.org/10.1253/circj.CJ-10-0052

View "Advance Publication" version (April 15, 2010).

Details

Abstract

Background: Overlapping drug-eluting stents might be associated with an adverse vessel response because of increased drug/polymer toxicity and lesion rigidity. Methods and Results: Lesions treated with overlapping everolimus- (EES=36) or paclitaxel-eluting stents (PES=38) were analyzed for 8-9-months by 3-dimensional intravascular ultrasound. EES were associated with significantly greater neointimal suppression in the single-strut regions than PES, with a similar trend in the overlap region. PES had significant vessel expansion in all regions, whereas there were no changes with EES. Neither stent fracture nor late incomplete stent apposition (LISA) in the overlap region was observed. Conclusions: Overlapping EES appears to be effective without vessel expansion, stent fracture or LISA for up to 8-9 months. (Circ J 2010; 74: 1023 - 1025)

Corresponding author

Register with J-STAGE for free!